Tissue Regenix Group PLC Sets up US subsidiary
November 26 2012 - 2:00AM
RNS Non-Regulatory
TIDMTRX
Tissue Regenix Group PLC
26 November 2012
Tissue Regenix sets up United States subsidiary
to target growing regenerative medicine market
Tissue Regenix appoints Greg Bila President, Tissue Regenix
USA
YORK, 26 November 2012. Tissue Regenix Group plc ('Tissue
Regenix') has set up a subsidiary company in the United States, as
part of its commercialisation strategy for its dCELL(R) technology
platform.
Tissue Regenix is also pleased to announce the recruitment of
Greg Bila from Kinetic Concepts Inc. ('KCI') as President of Tissue
Regenix USA. Greg's recent career at KCI has spanned a number of
sales & marketing roles and brings over 20 years' experience in
pharmaceutical and medical device fields.
Tissue Regenix will use its patented dCELL(R) technology to
target a number of areas. Work will focus initially on applying the
dCELL(R) to the treat a number of chronic diseases but, over time,
could be developed for other applications including vascular
repair, heart valve replacement and knee repair. Tissue Regenix's
dCELL(R) technology have delivered encouraging interim data.
Antony Odell, Managing Director of Tissue Regenix commented:
"This is a significant step in the development of Tissue Regenix.
It is an excellent signal of the strength of TR's proposition that
we can attract people of Greg's calibre and experience, we look
forward to advancing our plans in the US with him at the helm. The
United States presents an opportunity to establish our platform
dCELL(R) technology in a market potentially worth hundreds of
millions of dollars."
Greg Bila, President of Tissue Regenix Wound Care Inc. said: "I
am excited to be able to join Tissue Regenix at the beginning of
its expansion into the United States. TR's dCELL(R) technology will
be a welcome offering for the treatment of number of diseases and
the potential indications are attractive."
The potential advantages of the Company's dCELL technology over
other types of decellularised tissue scaffolds was underpinned at
Tissue Regenix technology day in October by Dr Alan Dardik,
Associate Professor of Surgery at Yale University, who has
conducted pre-clinical studies of Tissue Regenix dCELL(R) vascular
patch and published the results in the scientific journal PLoS
ONE.
Speaking about those studies Dr Dardik commented: "I have to say
my impression is it's the closest thing on the market to a tissue
engineered patch. It's the next technology. Other companies are
trying to attract stem-cells but they've already got the stem cells
that are coming into their patch."
ENDS
For Further Information
Tissue Regenix Group plc: 01904 435 176
Antony Odell
Newgate Communications:
Alistair Kellie 07801 234598
Andrew Adie 07970 256512
Martin Greig 07584 221513
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. The company's patented decellularisation
('dCELL(R)) technology removes DNA and other cellular material from
animal and human tissue leaving an acellular tissue scaffold which
is not rejected by the patient's body which can then be used to
repair diseased or worn out body parts. The potential applications
of this process are diverse and address many critical clinical
needs such as vascular disease, heart valve replacement and knee
repair.
Tissue Regenix was formed in 2006 when it was spun-out from the
University of Leeds. The company commercialises academic research
conducted by our partners around the World.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAUUOBRUAAAUAA
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jul 2023 to Jul 2024